WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
Guidelines
June 2017
HIV strategic information for impact
PQDx 0144-043-00 WHO
PQDx Public Report
November/2016, version 4.0
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
Accountability for the global health sector strategies, 2016–2021
WHO/CDS/HIV/19.7
Overwhelming evidence shows that a range of health concerns—mental illness, substance dependence, HIV/AIDS, and noncommunicable diseases—affect prisoners disproportionately. But, while incarceration poses risks to health—including inadequate nutrition and exposure to violence—prisons also pr...esent important opportunities to promote health and risk reduction that need to be tapped.
Some recommended remedies:
Health ministries, not ministries of justice, should manage health care responsibilities
Ensure that testing is available, but not mandatory, for infectious diseases
Make prison health part of the broader public health agenda
more
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
Editorial
Rev Panam Salud Publica 40(6), 2016
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
Technical Report
AIDS Medicines and diagnostics service
July 2015
Technical Report
AIDS Medicines and diagnostics service
September 2016
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05